CalDAG-GEFI deficiency protects mice in a novel model of FcγRIIA-mediated thrombosis and thrombocytopenia

Blood

Volumn 118, Issue 4, 2011, Pages 1113-1120

  Stolla, Moritz ^a   Stefanini, Lucia ^a   André, Pierrette ^a   Ouellette, Timothy D ^a   Reilly, Michael P ^a   McKenzie, Steven E ^a   Bergmeier, Wolfgang ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DIACYLGLYCEROL; FC RECEPTOR IIA; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PURINERGIC P2Y12 RECEPTOR; RAP1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GUANINE NUCLEOTIDE EXCHANGE FACTOR DEFICIENCY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; WESTERN BLOTTING;

EID: 79961004062     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-342352     Document Type: Article

References (33)

1. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol. 2006;81(1):36-44. (Pubitemid 43077211)
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535-555. (Pubitemid 36645375)
3. Reilly MP, McKenzie SE. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol. 2002;9(5):395-400. (Pubitemid 34864610)
4. Clawson CC, Rao GH, White JG. Platelet interaction with bacteria: IV. Stimulation of the release reaction. Am J Pathol. 1975;81(2):411-420.
5. Cines DB, Schreiber AD. Immune thrombocytopenia: use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med. 1979;300(3):106-111. (Pubitemid 9116290)
6. Sammaritano LR, Gharavi AE. Antiphospholipid antibody syndrome. Clin Lab Med. 1992;12(1):41-59.
7. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-181.
8. Grivas AA, Trafalis DT, Athanassiou AE. Implication of bevacizumab in fatal arterial thromboembolic incidents. J BUON. 2009;14(1):115-117.
9. Langer F, Ingersoll SB, Amirkhosravi A, et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost. 2005;93(6):1137- 1146. (Pubitemid 40823520)
10. McKenzie SE, Schreiber AD. Biological advances and clinical applications of Fc receptors for IgG. Curr Opin Hematol. 1994;1(1):45-52.
11. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999;162(7):4311-4318. (Pubitemid 29314823)
12. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
13. Reilly MP, Taylor SM, Franklin C, et al. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost. 2006;4(12):2687-2694. (Pubitemid 44741566)
14. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, McKenzie SE. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor. Blood. 2000;96(13):4254-4260.
15. Indik ZK, Salehuddin M, McKenzie SE, Kelly C, Levinson AI, Schreiber AD. Human Fc gamma RII: the structure of the Fc gamma RII cytosolic domain governs phagocytic function. Trans Assoc Am Physicians. 1992;105:214-221.
16. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997;16(9):2333-2341. (Pubitemid 27258634)
17. Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood. 1992;80(9):2261-2268.
18. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004;10(9):982-986. (Pubitemid 39273740)
19. Bergmeier W, Goerge T, Wang H-W, et al. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest. 2007;117(6):1699-1707. (Pubitemid 46871354)
20. Cifuni SM, Wagner DD, Bergmeier W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood. 2008;112(5):1696-1703.
21. Stefanini L, Roden RC, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood. 2009;114(12):2506-2514.
22. Torti M, Lapetina EG. Structure and function of rap proteins in human platelets. Thromb Haemost. 1994;71(5):533-543. (Pubitemid 24132947)
23. Chrzanowska-Wodnicka M. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115(3):680-687. (Pubitemid 40322242)
24. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
25. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520-2527.
26. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-135. (Pubitemid 40974717)
27. Hussain F, Philipp R, Zieroth S. HITT and stent thrombosis: a "clinical" diagnosis not to be missed. Int J Cardiol. 2009;133(1):e11-e13.
28. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost. 1995;74(6):1564-1572.
29. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69(4):344-350. (Pubitemid 23103121)
30. Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the Fc gamma II receptor. Br J Haematol. 1990;74(2):216-222. (Pubitemid 20041098)
31. Qi R, Ozaki Y, Kuroda K, et al. Differential activation of human platelets induced by Fc gamma receptor II cross-linking and by anti-CD9 monoclonal antibody. J Immunol. 1996;157(12):5638-5645. (Pubitemid 126448987)
32. Selleng K, Selleng S, Raschke R, et al. Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. Am J Hematol. 2005;78(3):188-192. (Pubitemid 40316495)
33. Stolla M, Stefanini L, Roden RC, et al. The kinetics of αIIbß3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood. 2011;117(3):1005-1013.